O

OmniAb Inc
NASDAQ:OABI

Watchlist Manager
OmniAb Inc
NASDAQ:OABI
Watchlist
Price: 3.92 USD 1.82% Market Closed
Market Cap: 463.2m USD
Have any thoughts about
OmniAb Inc?
Write Note

OmniAb Inc
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

OmniAb Inc
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
O
OmniAb Inc
NASDAQ:OABI
Retained Earnings
-$39.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Retained Earnings
$51.4B
CAGR 3-Years
15%
CAGR 5-Years
19%
CAGR 10-Years
18%
Danaher Corp
NYSE:DHR
Retained Earnings
$43.3B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
8%
Mettler-Toledo International Inc
NYSE:MTD
Retained Earnings
$8.1B
CAGR 3-Years
13%
CAGR 5-Years
14%
CAGR 10-Years
14%
Agilent Technologies Inc
NYSE:A
Retained Earnings
$773m
CAGR 3-Years
105%
CAGR 5-Years
N/A
CAGR 10-Years
-19%
IQVIA Holdings Inc
NYSE:IQV
Retained Earnings
$5.6B
CAGR 3-Years
43%
CAGR 5-Years
42%
CAGR 10-Years
N/A
No Stocks Found

OmniAb Inc
Glance View

Market Cap
471.3m USD
Industry
Life Sciences Tools & Services

OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 93 full-time employees. The company went IPO on 2020-10-09. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. Its OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach and OmniTaur features structural attributes of cow antibodies for complex targets. The firm's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic targets.

OABI Intrinsic Value
4.35 USD
Undervaluation 10%
Intrinsic Value
Price
O

See Also

What is OmniAb Inc's Retained Earnings?
Retained Earnings
-39.4m USD

Based on the financial report for Dec 31, 2023, OmniAb Inc's Retained Earnings amounts to -39.4m USD.

Back to Top